SHENYANG, China, Aug. 15, 2011 /PRNewswire via COMTEX/ -- 3SBio Inc. /quotes/zigman/104779/quotes/nls/ssrx SSRX +2.81% ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter and first half ended June 30, 2011.

Second Quarter 2011 Financial Highlights:

Total net revenues increased by 29.0% over the second quarter of 2010 to RMB136.1 million (US$21.1 million), compared to RMB105.5 million (US$15.6 million) in the second quarter of 2010.

Operating income was RMB30.1 million (US$4.7 million), compared to operating income of RMB27.9 million (US$4.1 million) in the second quarter of 2010.

Net income was RMB30.4 million (US$4.7 million), compared to net income of RMB25.5 million (US$3.8 million) in the second quarter of 2010.

Net income per American Depositary Share ("ADS") on a fully-diluted basis was RMB1.34 (US$0.21) compared to net income per ADS on a fully-diluted basis of RMB1.16 (US$0.17) for the second quarter of 2010.

Cash, cash equivalents and time deposits were RMB725.6 million (US$112.3 million, including restricted cash of RMB0.7 million) at June 30, 2011.

First Half 2011 Financial Highlights:

Total net revenues increased by 26.0% over the first half of 2010 to RMB254.4 million (US$39.4 million), compared to RMB201.9million (US$29.8 million) in the first half of 2010.

Operating income was RMB54.3million (US$8.4 million), compared to operating income of RMB56.1 million (US$8.3 million) in the first half of 2010.

Net income was RMB52.5 million (US$8.1million), compared to net income of RMB52.2 million (US$7.7 million) in the first half of 2010.

Net income per American Depositary Share ("ADS") on a fully-diluted basis was RMB2.34 (US$0.36) compared to net income per ADS on a fully-diluted basis of RMB2.37 (US$0.35) for the first half of 2010.